Investigation of the Effect of Upper Gastrointestinal Disease on the Pharmacokinetics of Oral Semaglutide in Subjects With Type 2 Diabetes.

NCT02877355 · Completed

Last updated 2026-05-28

This clinical trial is testing how upper gastrointestinal diseases affect how the body absorbs oral semaglutide in adults with type 2 diabetes.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 55 people

Who can join Ages 18–80 · all sexes

Timeline Started 2016-08 · est. completion 2017-11

Where 2 sites · Germany

What this study is testing ClinicalTrials.gov NCT02877355 ↗

Description as written by the study sponsor.

This trial is conducted in Europe. The aim of this trial is, to investigate the effect of upper gastrointestinal disease on the pharmacokinetics (the exposure of the trial drug in the body) of oral semaglutide in subjects with type 2 diabetes.

Treatments tested

semaglutide Drug

All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days

Main thing measured	Area under the semaglutide plasma concentration-time curve
Sponsor	Novo Nordisk A/S
Conditions studied	Diabetes, Diabetes Mellitus, Type 2
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02877355 ↗